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Abstract
Parkinson’s disease (PD) is one of the most common neurodegenerative disorders of aging, characterized by the
degeneration of dopamine neurons (DA neurons) in the substantial nigra, leading to the advent of both motor
symptoms and non-motor symptoms. Current treatments include electrical stimulation of the affected brain areas
and dopamine replacement therapy. Even though both categories are effective in treating PD patients, the disease
progression cannot be stopped. The research advance into cell therapies provides exciting potential for the
treatment of PD. Current cell sources include neural stem cells (NSCs) from fetal brain tissues, human embryonic
stem cells (hESCs), induced pluripotent stem cells (iPSCs) and directly induced dopamine neurons (iDA neurons).
Here, we evaluate the research progress in different cell sources with a focus on using iPSCs as a valuable source
and propose key challenges for developing cells suitable for large-scale clinical applications in the treatment of PD.
Keywords: Parkinson’s disease, Dopamine neuron, Neural stem cell, Human embryonic stem cells, Induced
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Introduction
Parkinson’s disease (PD) is one of the most common neu-
rodegenerative disorders of aging, affecting about 1 % of
the population aged 60 years and older and 3–5 % of the
population above the age of 85 [1].
Clinically, patients with PD are characterized with
both motor and non-motor symptoms. Motor symp-
toms, being far more noticeable, have typically been used
in clinical diagnosis. The various disruptions in motor
control include muscle rigidity, resting tremors, bradyki-
nesia (slowness of movement), and postural instability,
and typically appear when 60–80 % of dopamine (DA)
neurons in the substantia nigra are degenerated [2]. The
reliable identification of non-motor symptoms is important
as many non-motor symptoms, including depression, cog-
nitive dysfuction, pain, and sleep disorders, precede the
motor dysfunctions; not only is management of these
symptoms important for quality of life, but early diagnosis
of PD could also be key for effective treatment [3].
Because DA neurons degenerate to cause a drop in
dopamine release, current treatments for PD include
dopamine replacement drugs such as levodopa to in-
crease dopamine levels, dopamine inhibitor carbidopa to
reduce dopamine degradation in the peripheral blood
[4, 5], and deep brain stimulation (DBS) to the nucleus
subthalamicus [6]. Even though dopamine replacement
drugs and DBS are effective in improving the symptoms
of the patients, they cannot stop the disease progression.
Moreover, current medications can cause the develop-
ment of dyskinesia (involuntary muscle movements), ef-
fectively “overshooting” the clinical symptoms of PD.
Recent research progress has provided treatment poten-
tial through replacing lost DA neurons using neural
stem cells (NSCs) or fully differentiated DA neurons
from fetal brain tissue, embryonic stem cells (ESCs),
mesenchymal stem cells (MSCs) sourced from adults or
fetuses, and induced pluripotent stem cells (iPSCs) re-
programmed from patients’ somatic fibroblasts or blood
cells. Much work has been done to adapt cells from vari-
ous sources to potential clinical applications to improve
treatments for neurodegenerative diseases including PD
[7, 8].
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Etiology and pathological mechanisms
The causes of PD can be characterized as genetically
susceptible genes and environmental toxic factors such
as the pesticide rotenone and heavy metal manganese,
which implicate oxidative damage and mitochondrial
impairment leading to degeneration of dopamine neu-
rons in PD [9–13]. The majority of PD cases are spor-
adic or idiopathic with unknown aetiology (80–90 % of
PD cases), but a minority of cases (with estimates ran-
ging from 10 to 20 % of PD cases) are familial and can
be linked to a particular monogenic mutation or associ-
ated to PD related genes. The twin studies have sug-
gested that this finding can be explained by the fact that
genetic factors do not play a major role in causing typ-
ical PD, particularly with regards to disease incidence
after 50 years of age [14]. They suggested that genetic
factors are only an important factor when the disease
begins at or before the age of 50, a relatively rare occur-
rence. The most well-characterized mutation loci for
early-onset autosomal recessive PD are PARK2(Parkin) ,
PINK1, and PARK7, ATP13A2 whereas those for the
autosomal dominant form of PD are SCNA and LRRK2.
The susceptible genes associated with PD are Tau, Nurr1
and GBA. SCNA, which codes for alpha-synuclein, has
been particularly well-studied; triplication of the locus
has been associated with an aggressive form of PD that
advances into cognitive impairment [15, 16]. There is
ongoing debate as to the exact balance between the gen-
etic and environmental factors mainly because the ac-
curacy of clinical diagnosis of idiopathic PD has been
disputed [17]. Some other reasons of the difficulties as-
sociated with assessing the disease etiology may be the
result of inconsistent diagnostic criteria among heteroge-
neous populations of PD patients for study.
Pathologically, PD is involved in the degeneration and
loss of dopamine (DA) neurons located in the substantia
nigra of the the midbrain [18]. These DA neurons pro-
ject to the basal ganglia (the striatum), which is heavily
involved in motor control and function [19]. The loss of
DA neurons is accompanied by lewy bodies and lewy
neurites, which are mainly formed by insoluble aggre-
gates of alpha-synuclein (coded by SCNA) and Tau pro-
tein and might hamper the survival and dendritic
development of newborn neurons [20, 21]. The spread
of lewy bodies in the brain causes motor symptoms ac-
companied by an intensification of the disease, including
cognitive impairment that encompasses hallucinations,
dementia, and speech difficulties [22, 23].
Stem cell sources for the treatment of PD
Several stem cell sources for the treatment of PD have
been studied in the past decades and summarized in
Fig. 1. Some studies used adult bone marrow-derived
mesenchymal stem cells (BM-MSC) and olfactory en-
sheathing cells (OEC) [24–26], but these cells have lim-
ited ability to differentiate to dopamine neurons.
Currently neural stem cells (NSCs) and dopamine neu-
rons from fetal brain tissue, embryonic stem cells
(ESCs), induced pluripotent stem cells (iPSCs) and dir-
ectly induced dopamine neurons (iDA neuron) repro-
grammed from autologous somatic cells have been
widely studied to move these cells into bedside [27–29].
NSCs and dopamine neurons from fetal brain tissue
Neural stem cells (NSCs) were first reported in 1965 [30]
and were described as granule cells with a high rate of
proliferative activity in the cortex of brains. As a multipo-
tent stem cell population, NSCs have neural potential and
Fig. 1 Different stem cell sources for the treatment of PD
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can differentiate into neurons, astrocytes and oligodendro-
cytes. NSCs can be also isolated from the other regions of
fetal brains or from the hippocampus and subventricular
zone (SVZ) of the adult mammalian brain, the areas where
neurogenesis continues throughout the animal’s lifespan [31,
32]. Since initial discoveries of NSCs, there have been many
advances in the isolation, expansion, and differentiation of
NSCs [33, 34]. Mouse and human NSCs transplanted into
the rat brain migrate and differentiate in a site-specific man-
ner. Moreover, Nishino et al. reported that these NSCs ap-
pear to differentiate preferentially into DA neurons in PD
model rats with depleted host DA levels [35].
NSCs can be also induced to differentiate into specific
neural cells in vitro prior to transplantation. Some
homeodomain transcription proteins were isolated and
selectively expressed in DA neural progenitors in the
ventral midbrain, and it was found that Lmx1a and
Msx1 function as lineage determinants triggering gener-
ation of DA neurons with midbrain identity. These fac-
tors were shown to initiate the differentiation of neural
progenitor cells in chick embryos into midbrain DA neu-
rons. These findings suggested that Lmx1a and Msx1
play important roles in the specification and maturation
of DA neurons. NSCs were differentiated into DA neu-
rons via a five-step protocol similar to the culture condi-
tions used to differentiate ESCs demonstrated the
morphological characteristics of forebrain DA neurons.
Kim et al. reported that overexpressing the transcription
factor ASCL1 was able to regain neurogenesis from hu-
man neural progenitor cells and produced larger neu-
rons with more neurites [36]. The identification of
NURR1 mutation in PD patient suggested that NURR1
plays regulatory role in the development of DA neurons
[37]. Forcing overexpression of Nurr1 was found to en-
hance the ability of mouse NSCs to differentiate into DA
neurons and survive in vivo in PD rat models [38].
Animal studies showed that rodent and human fetal
brain dopamine neurons transplanted to the midbrain of
the 6-OHDA-lesioned rats survived well in the host
brains and improved the motor defects of the PD rats
[39]. Even though some studies reported limited recov-
ery after transplanting fetal substantia nigra-derived cells
into rat PD models, most found very promising results
[40, 41]. Redmond et al. reported fetal ventral mesenceph-
alic (VM) tissue transplanted to the 1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (MPTP)-lesioned African Green
Monkeys (AFG) survived well in the host brains, and all
animals showed significant behavioral improvement in pri-
mate model of PD by 9 months post-transplantation [42].
Based on the animal studies, the first clinical trials began in
Sweden in the late 1980s to transplant fetal dopaminergic
neurons or tissue to PD patients in placebo-controlled pro-
tocols [43]. Subsequently, the clinical assessment protocols
were modified to use the quantitative measurements of
motor function, and several clinical trials were conducted
to transplant human fetal brain-derived dopamine neurons
to PD patients. In terms of behavioural and histological im-
provements, significant effects were found in these small-
case studies [44, 45]. Freed et al. performed double-blind,
sham surgery-controlled study by selecting 40 patients with
mean PD duration of 14 years and randomly dividing the
patients into two groups of 20 patients each. The trans-
plantation group was injected with fetal brain neural cells
bilaterally whereas the control group received sham sur-
gery. All the patients were evaluated at one year after trans-
plantation based on the Unified Parkinson’s Disease Rating
Scale (UPDRS). As a result, significant improvements were
found for younger PD patients at the age of 60 years old
and younger whereas no significant improvements were
found in older patients compared to the control group, im-
plying that the therapeutic efficacy varied in certain sub-
populations [45]. In general, clinical trials have had
extremely variable functional outcome, though solid im-
provements need to be further determined by clinical and
imaging evaluations [46, 47]. Olanow et al. performed an-
other double-blind controlled clinical trial with 34 severe
PD patients for two years after transplantation. Patients
were randomly received bilateral transplantation of fetal ni-
gral neural cells as transplantation group or sham surgery
as control group. Overall no significant therapeutic effects
were in transplantation group versus the control group
even though robust survival of dopamine neurons was ob-
served at postmortem examination [48]. Interestingly in an-
other double-blind study, 33 patients who were
transplanted with fetal brain dopamine neurons were
followed for 2 years and 15 of these patients were followed
for 2 more additional years, a significant clinical improve-
ment in UPDRS motor ratings and increase in putamen up-
take on (18)F-fluorodopa ((18)F-FDOPA) PET indicated
the viability of the fetal brain grafts in PD patients over the
4 year course of the study [49].
However, fetal brain tissue transplantation did not es-
cape the side effect of dyskinesia, prevalent in more
traditional levodopa treatments for PD. Olanow et al.
found that 56 % of patients into which fetal mesenceph-
alic tissue was transplanted developed persistent dyskin-
esia after overnight withdrawal of dopaminergic
medication [48] – far more than 15 % of patients experi-
encing dyskinesia Freed et al. reported [45]. Though its
exact prevalence may be contested, the recurrence of
dyskinesia following neural transplantation has been
well-documented [46, 50]. There is evidence that grafts
containing serotonin neurons are more likely to have
this detrimental effect and that dyskinesia may therefore
be alleviated by ensuring a homogeneous cell population
in transplantation [51, 52]. In order to know the long-
term results with fetal brain cell transplantation, three
individual clinical trials were studied. One study found
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that transplanted fetal midbrain DA neurons survived
without pathology after up to 14 years, suggesting the
safety and feasibility of transplanted fetal brain cells for
the treatment of PD [53], other two studies found that
alpha-synuclein-positive lewy bodies eventually spread to
the transplanted DA neurons in PD patients after 14 or
16 years of transplantation [54, 55]. These pathological
changes suggest that PD can be an ongoing process.
The discrepancy may be the result of the difference
between genetically and environmentally caused PD – a
case of PD caused by genetic mutations would be an on-
going process, whereas a case of PD caused by environ-
mental factors might be halted by the infusion of healthy
cells. Therefore, it cannot be conclusively stated that DA
neuron engraftment is a universally permanent treat-
ment for PD; follow-up implantations may be required
for optimal effectiveness. However, fetal midbrain cell
transplantation did provide PD patients, on average,
symptomatic improvements when compared to control
groups, but it is not a recommendable therapy for PD
unless significant improvements are made and issues re-
garding to consistency of improvements, recurrence of
dyskinesia, and eventual spread of pathology are over-
come. There is also, like all other allogeneic treatments,
a risk of graft rejection – the fact that the midbrain tis-
sue with which a patient is being treated has been
sourced from a genetically distinct individual, causing
immunogenic responses that must be repressed in the
study [56, 57].
Moreover, the use of fetal primary tissue for PD treat-
ment is not scalable, given the procurement difficulty
and ethical concerns behind the use of NSCs from fetal
brain tissues. Overall, the clinical trials with NSCs of
fetal brains showed some improvements of symptoms
and the survival of the transplanted cells in PD patients,
but some results are controversial because of the limited
cases or diversities of the PD patients [47]. Some of the
clinical trials with fetal brain- derived NSCs or dopa-
mine neurons are summarized in Table 1.
In order to further address the therapeutic effects of
the transplanted NSCs for patients, a new multicenter
and collaborative study of the European Union
(TRANSEURO) was formed in 2010 to make new guide-
lines for clinical trials of fetal brain-derived cell therapy
in PD. These include careful selection of patients: aged
30–68 at the time of inclusion, showing a good response
to levodopa; early in the course of their disease (disease
duration 2–10 years); systematic evaluation of cell prep-
aration location of transplantation; clinical assessment
standards; numbers of patients and; immunosuppression
after transplantation and follow-up time. This study has
completed the new clinical trial for more than 100 PD
patients and results are in the analysis [58, 59]. A signifi-
cant clinical outcome was recently reported in two PD
patients who were transplanted with fetal ventral mesen-
cephalic cells and were followed up to 15 and 18 years
post-transplantation. The motor improvement was ob-
served in the first year and continued to 18 years after
transplantation with discontinued levo-dopa replace-
ment therapy [60].
Human embryonic stem cells (hESCs)
Embryonic stem cells (ESCs) are pluripotent, self-
renewing, and isolated from the inner cell mass of the
pre-implantation blastocysts [61]. ESCs can therefore be
differentiated into any kind of tissue cells, including
Table 1 Summary of the clinical trials using fetal brain cells for treatment of PD














1 12 months 1/1 Yes No Not available [43]
6 10–72
months
4/6 Yes No Not available [77]
5 18–24
months
2/5 Yes No Not available [36]
20/40 3 years 17/20 Yes No Not available [45]
23/34 24 months 6/23 Yes 56 % dyskinesia Not available [48]
2 8 years 2/2 Yes 50 % dyskinesia Not available [7]
5 9–14 years Not available Yes Not available Not available [42]
1 14 years 1/1 Yes Dyskinesia Lewy body [55]
2 11–16 years Not available Yes Not available Lewy body [54]
33 2–4 years 45 % Yes Not available Not available [8]
3 13–16 years Yes Yes Not available Not available [8]
2 18 and
15 years
2/2 Yes Not available Not available [24]
Note: 20/40 and 23/34 indicates that 20 of 40 patients and 23 of 34 patients are in the cell transplantation group and the other patients are in the control group
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neural stem cells (NSCs), neurons and DA neurons.
Mouse embryonic stem cells-derived NSCs, or fully dif-
ferentiated neurons and dopamine neurons have been
shown to have neuroprotective effects for the treatment
of PD [62–64].
Human embryonic stem cells (hESCs) were first iso-
lated by culturing inner cell mass cells with feeder cells
of mouse embryonic fibroblasts (MEFs) [65]. In the past
two decades, strategies have been developed to direct
the hESC differentiation into the neural stem cells and
neurons, in particular dopamine neurons for PD. Studies
have shown the differentiation of hESCs into midbrain
dopamine (DA) neurons by the application of specific
patterning molecules that regulate midbrain develop-
ment in vivo [66, 67]. Transplantation of hESCs-derived
neural precursor cells to the PD rats showed that grafted
cells differentiated DA neurons in vivo and development
of protocol for producing more DA neurons in vitro is
required [68]. Moreover, Yan et al. developed protocols
for generating specifically midbrain-like DA neurons
from hESC-derived neuroepithelial cells by applying
growth factors SHH and FGF8 in a specific sequence
[69]. Their study suggested that early exposure to
growth factor FGF8 and SHH instructs early precursors
to adopt a region identity leading to differentiation of
midbrain neuroepithelial cells. These hESC-derived
dopamine neurons were able to improve the locomotive
deficits of PD rat models, provided that grafted hESC-
derived dopamine neurons functioned in vivo [70]. In
order to increase the efficiency of DA production from
pluripotent stem cells, Chamber et al. developed a
protocol by inhibiting SMAD signalling to enhance pro-
liferation and survival of midbrain DA neurons from
hESCs [71]. They reported that addition of Noggin and
SB431542 for inhibiting SMAD signalling induces
complete neural conversion of >80 % of hESCs under
adherent culture conditions. Fasano et al. have reported
that neurons in developmental default towards anterior
regionalization, but may be shifted towards a midbrain-
like identity by FGF8 or Wnt1 treatment [72]. In order
to further improve complete conversion of hESCs to the
dopamine neurons and decrease the teratoma potential
in vivo, the same group developed a floor-plate-based
method for generating hESCs-derived DA neurons in a
differentiation medium containing activators of sonic
hedgehog (SHH) and canonical WNT signalling in vitro.
They found that these DA neurons efficiently grew for
more than 18 weeks and restored the amphetamine-
induced rotation dysfunctions in vivo after being trans-
planted into 6-OHDA-lesioned rats and MPTP-lesioned
rhesus monkeys [73]. Muramatsu et al. implanted NSCs
derived from cynomolgus ES cells unilaterally in the pu-
tamen of neurotoxin- lesioned cynomolgus monkeys.
They found that transplantation of NSCs derived from
cynomolgus monkey ES cells can restore DA function in
a primate model of PD [74]. Another group reported
that using lentiviral vectors to express the key DA
neuron-regulating gene, LMX1A, in hESCs produced
ventral midbrain DA neurons of the A9 subtype which
account for more than 60 % of all neurons generated
from LMX1A-transfected hESCs [75]. To determine the
functional properties of hESC-derived DA neurons in
vivo, hESC-derived midbrain dopamine neurons and
fetal brain DA neurons were engrafted into rat models
of PD. MRI and PET imaging analysis showed that
grafted hESC-DA neurons survived, projected long
neural branches, and played similar functions to improve
the locomotive deficits of PD rats as fetal brain DA neu-
rons, providing further preclinical evidence of hESC-
derived dopamine neurons for treatment of PD [76].
The major concerns to use stromal cell as feeder cells
for culturing hESCs-derived cells for clinical purpose are
that hESCs-derived cells contain some rodent cells and
may increase the risk of immune rejections. To over-
come this problem, some studies developed feeder-free
culture system to use matrigels to replace the feeder
cells [36, 77]. Schulz et al. moved towards clinical applic-
ability by generating the neurons in a serum-free sus-
pension system [78]. Vazin et al. were successful in
replacing the PA6 stromal cells with growth factors
SDF-1, PTN, IGF2, and EFNB1, which induced the dif-
ferentiation of hESCs directly into TH-positive DA neu-
rons [79]. Growth factors SHH and FGF8 were reported
to substitute for PA6 stromal cells in generating DA cells
after an initial induction step of differentiating hESCs
into NSCs. They endeavoured to develop a scalable
process applicable to the clinic and easily brought to
Good Manufacturing Protocol (GMP) standards. Their
culture protocols did not involve serum, but they made
the important discovery that cells could be stored at
each of the intermediate stages in their four-step process
(propagation of ESC→ generation of neural stem cells
(NSC)→ induction of dopaminergic precursors matur-
ation of dopaminergic neurons) without loss of func-
tional ability, allowing cells to be transplanted at an
appropriate time point in neural development [80].
Although hESCs can be efficiently differentiated
into a large amount of DA neurons in vitro and
showed solid functions to restore the motor dysfunc-
tions in PD animal models, including mice, rats and
non-human primates, clinical trials have not been
performed for treating PD patients. The main prob-
lems with hESCs are: i) the phenotypic stability of
hESC-derived dopamine neurons after transplantation,
and ii) the worry about residual undifferentiated
hESCs within the large numbers of cells that need to
be injected for human therapy. The residual undiffer-
entiated hESCs might indeed lead to tumor formation
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even if this is not observed anymore in rodent experi-
ments. In addition, some ethical concerns and prob-
lems of immune rejection also limited the clinical
applications of hESCs.
Induced pluripotent stem cells (iPSCs)
Earlier studies showed that differentiated somatic cells
could be reprogrammed to an undifferentiated state using
somatic cell nuclear transfer (SCNT). SCNT technology
made the cloned lambs and cows available [81–83]. But
generating patient-specific cells using this technique has
not yet occurred [84, 85]. The successful generation of
mouse iPSCs was first reported in Yamanaka lab in 2006
by lentiviral expression of four transcription factors: Oct3/
4, Sox2, c-Myc, and Klf4 in mouse embryonic fibroblasts
[86]. Soon afterwards, the Yamanaka lab, as well as other
labs, used the human orthologs of these four transcription
factors (OCT4, SOX2, c-MYC, KLF4), or OCT4, SOX2,
NANOG and LIN28, to generate human iPSCs and pa-
tient- specific iPSCs with different diseases, including PD
[86–88]. The implication of Oct3/4 and Sox2 was unsur-
prising as previous research defining their essential role in
the propagation of undifferentiated ESCs in culture [89].
The roles of Klf4 and c-Myc were promoting reprogram-
ming of somatic cells. Later studies indeed showed that
Oct3/4 and Sox2 appear to be the only genes indispensable
in generating iPSCs [90] whereas Klf4 and c-Myc are dis-
posable [91]. iPSCs share most of their characteristics with
ESCs; they are pluripotent and self-renew indefinitely.
However, they are generated via reprogramming the
already-differentiated somatic cells of an organism back to
their embryonic-like pluripotent state. Overcoming the
problems associated with fetal NSCs and hESCs, iPSCs
generated from patients will have wide applications for ex-
ploring the molecular mechanisms and cell-based therapy
of neurodegenerative diseases [28, 86, 88, 92].
One of the major advantages of iPSCs over other cell
types in clinical applications is that iPSCs can be gener-
ated from the cells of the individual being treated; the
cultured cells will be autologous. This key trait of iPSCs
theoretically minimizes the risk of rejection and en-
hances their integration into the brain tissues of patients
with PD. Moreover, the ethical issues of using aborted
fetuses as a cell source are circumvented. Once repro-
grammed into iPSC state, the iPSCs can be systematic-
ally exposed to specific factors that direct the cells to
differentiate into a specific lineage (such as NSCs or DA
neurons) [93, 94]. Much research has been done to im-
prove the generation, differentiation, and potential clin-
ical applications of iPSCs, with particular efforts made to
bring these therapeutic cells to GMP (Good Manufactur-
ing practice) standards such that they can be translated
to the clinic for treatment of neurodegenerative diseases
such as PD [95]. iPSCs have also been used in drug
screening and discovery and as a disease model to study
the molecular mechanisms of the disease [96].
To determine the clinical potential of iPSCs-derived
cells, the therapeutic effects of mouse iPSCs were stud-
ied by transplanting the iPSCs into rat brains [97]. They
found that grafted iPSCs matured into midbrain-like
dopamine neurons, resulting in behavioural improve-
ments in rat PD models. In other studies, human iPSCs-
derived neurons or neural stem cells showed therapeutic
effects in rat and monkey PD models [9, 98–100]. Even
though many studies indicated the iPSCs induced im-
provement of motor function in animal PD models, no
clinical trials have been reported using human iPSCs for
the treatment of PD patients. Because the integration of
viral vectors and transgenes in the genome of iPSCs
from patients may affect their differentiation potential or
induce malignant transformation, Jaenish et al. derived
PD patient-iPSCs free of transgenes using Cre-
recombinase to excise the reprogramming factors. These
patient-iPSCs showed a global gene expression profile
more closely related to hESCs and hiPSCs carrying the
transgenes [101]. DA neurons from the iPSCs with the
LRRK2 mutation (G2019S) were found to be sensitive to
oxidative stress and have increased expression of key
oxidative stress-response genes and α- synuclein aggre-
gation [102]. After correction of the LRRK2 G2019S mu-
tation in iPSCs, the degenerated DA neurons was
rescued, supporting the idea that LRRK2 mutation plays
important roles in the pathogenesis of PD [103]. Emborg
et al. reported that autologous transplantation of rhesus
monkey iPSC-derived neural progenitors to the brain of
MPTP-induced hemiparkinsonian rhesus monkeys sur-
vived well and differentiate into neurons, astrocytes, and
myelinating oligodendrocytes [104]. Isacson et al. used
stromal feeder cell-based protocol to differentiate the
virus-free PD-iPS cells into DA neurons and trans-
planted the DA neurons into the 6-OHDA- lesioned
rats. They found that these DA neurons survived and
mediated functional improvements in PD rats by redu-
cing apomorphine-induced rotational asymmetry [98].
The same group producted the midbrain dopamine neu-
rons derived from the cynomolgus monkey (CM) iPSC
and autologously transplanted into the MPTP-lesioned
CMs. They found that autologous iPSC dopamine neu-
rons can provide long-term functional recovery and
transplanted cells survive for up to 2 years and reinner-
vate the host brain [105]. Recently, we worked all the
way from isolation of skin fibroblasts of PD patients and
control individuals, to the generation of iPS cells by
retrovirus-mediated expression of OCT4, SOX2, c-MYC
and KLF4, to the differentiation of iPS cells to neural
stem cells (NSC) and DA neurons, and finally to the
transplantation of the iPS cells-derived NSCs to the
striatums of the 6-OHDA-induced PD rats. We found
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that iPS cells carrying the transgenes can also be differ-
entiated into the DA neurons in vitro as well as survive
and be differentiated into neurons and DA neurons in
PD rats. The grafted iPS cells-NSCs significantly im-
proved the motor defects of PD rats from the 4th week
to the 16th week [9]. Our results showed that iPS cells
carrying the transgenes can be differentiated into DA
neurons in vitro and in vivo; however, the differentiation
efficiency of neurons and DA neurons need to be further
improved by modifying the cell culture protocols, including
growth factors and iPS cells together for transplantation, or
increasing the dose of immune-suppressive agents to re-
duce the immune-rejection against the human-derived
cells.
Research advances have been made towards improving
effectiveness of iPSC generation in the absence of c-Myc.
Inhibitors of DNA methyltransferase, histone deacetylase,
and valproic acid (VPA) were reported to improve repro-
gramming efficiency, particularly improving efficiency by
two orders of magnitude – up to 10 % – without induction
of c-Myc. Stadtfeld et al. used non- integrating,
replication-incompetent adenoviruses expressing the
classic four transcripton factors to reprogram mouse
liver cells into iPSCs [106]. Okita et al. developed a
protocol by which repeated transfection of plasmids
containing the appropriate genes (one containing the
complementary DNAs of Oct3/4, Sox2, and Klf4; the
other, c-Myc) into embryonic fibroblasts, resulting in
iPSC cells [107]. This protocol was adapted for use in
human cells by Kaji et al. [108], though the trans-
poson piggyBac was utilized in the process, with the
risk of residual sequences and chromosomal distrup-
tions. A further approach to iPSC generation has
been the use of nonintegrating episomal vectors,
which allows the derivation of iPSCs that are com-
pletely free of vector and transgene sequences [109].
The DNA vector-free, direct protein transduction system
was also proposed to generate iPSCs to eliminate potential
risks associated with chromosomal integrations and muta-
tions [110]. Consistent similarity in cellular and differenti-
ation properties were found between hiPSCs from
integrating and non-integrating reprogramming factors
[7] . But one study showed that protein-based reprogram-
ming of cells into hiPSCs resulted in cells that behaved
most similarly to hESCs, without showing obvious ex-
ogenous reprogramming gene expression [111].
A major limitation for current ES/iPS cell differenti-
ation protocols is the lack of clinical-grade DA neurons
with a stable phenotype, the A9-subtype ventral mid-
brain DA neurons. To overcome this problem, Isacson
et al. have developed an efficient differentiation and sort-
ing strategy for DA neurons from both human ES/iPS
cells. The NCAM (+) /CD29 (low) enriched VM DA
neurons were sorted from pluripotent stem cell-
differentiated neural cells. Molecular studies showed that
the sorted neurons were positive for FOXA2/TH and
EN1/TH and had increased expression levels of FOXA2,
LMX1A, TH, GIRK2, PITX3, EN1, and NURR1, indicat-
ing that the sorted neural cells are DA neurons. After
transplantation, this population of iPSC-derived DA
neurons was able to restore motor function of 6-OHDA-
lesioned rats. The transplanted sorted cells were found
to be integrated in the rat brain tissue with TH
+/hNCAM+ staining in the host striatum. This study
provided experimental evidence for the feasibility and
safety of iPSC-derived cell therapies in the future [99].
Another issue is the similarities and differences between
iPSCs and ESCs. Several groups succeeded in generating
both mouse iPSCs and human iPSCs epigenetically and
developmentally identical to ESCs through improvement
of end points for the reprogramming process [112, 113].
Modifications have also been made in a bid to reduce the
mutagenic potential of the retroviruses and lentiviruses
being used. For example, the reactivation of the c- Myc
retrovirus particularly increases the risk of mutations,
hence increasing the posibility of tumerogenicity [114].
Substituting Nanog and Lin28 for Klf4 and c-Myc [88] has
been found to be one way to reduce this risk. However,
eliminations of c-Myc from the protocol resulted in far
lower efficiency of iPSC formation. This suggests that the
role of c-Myc is to accelerate proliferation or otherwise en-
hance the speed of events establishing pluripotency, while
not being necessary in the establishing of pluripotency it-
self [115]. Though the generated iPSCs were very similar
to ESCs in morphology, growth properties, and differenti-
ation into different germ layers, differences between ESCs
and iPSCs were detected; this may be caused by using dif-
ferent iPSC lines [116]. In order to know the similarity
and difference between iPSCs and hESCs at the molecular
levels, Koyanagi-Aoi et al. analysed 49 human iPSC lines
and 10 hESC lines. They found that only two iPSC lines
have varied gene expression and DNA methylation. In
vitro neural differentiation was compared between 40
human iPSC lines and 10 hESC lines, and only 7
iPSC lines had some undifferentiated cells after neural
differentiation and formed teratoma when trans-
planted into mouse brains. This study indicated that
iPSCs are very similar to hESCs with some difference
in the specific iPSC lines [117].
Once again, it is important to note that such protocols
must be adapted to a xeno-free, scalable system for the
clinic. Rodriguez-Piza et al. [118] reprogrammed human
fibroblasts to iPSCs under strict xeno-free conditions,
providing a path to GMP applicability. Chen et al. de-
scribed a suspension culture system for hESCs which
was adapted by O’Brien [119] and Laslett [120] for use
in hESCs and hiPSCs (reviewed by Serra et al. [121]).
Such systems allowed long-term culture while retaining
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normal karyotype, appropriate marker expression, and
pluripotency, and moreover allowed cryopreservation of
cells. The future direction of pluripotent stem cell gener-
ation for clinical use lies in the use of such suspension
culture bioreactors, with the added challenge of main-
taining quality-control of the derived cells. To reduce
the effects of transgenes on functions of the iPS cells,
several labs developed methods to use two or three fac-
tors to generate iPS cells. Deng et al. reported that iPS
cells can be generated from mouse embryonic and adult
fibroblasts by a single factor of OCT4 in combination
with small molecules of VPA, CHIR 99021, and TGF-β
inhibitor [91]. A recent study indicated that the deriv-
ation of rhesus monkey naive iPSCs can be obtained
with only small molecules, omitting the OCT4, provid-
ing a valuable cell source for use in preclinical research
and disease modeling [122].
Directly induced dopamine neurons (iDA neurons)
Though iPSCs give great potentials to the cell-based
therapy for PD, the complicated procedures for gener-
ation, characterization, and differentiation into the DA
neurons push the researchers to find other convenient
methods to obtain DA neurons. In addition, the human
iPSC-derived neural stem cells or dopamine neurons
may contain the undifferentiated cells which can cause
tumor formation and limit their clinical application. Dir-
ect generation of iDA cells from somatic cells might
have significant implications for understanding critical
processes for neuronal development in vitro disease
model and cell replacement therapies. One of the other
approaches is to directly induce the fibroblasts of PD pa-
tients to DA neurons (iDA neurons). Recent studies have
reported the success of generating DA neurons by
directly reprogramming the fibroblasts with different
combinations of transcription factors Mash1 (Ascl1),
Nurr1 (Nr4a2), Lmx1a, Ngn2, Sox2, and Pitx3 [123–125].
Caiazzo et al. first reported the production of the
dopamine neurons directly reprogrammed from human
and mouse fibroblasts. They identified three transcrip-
tion factors, Mash1 (Ascl1), Nurr1 (Nr4a2) and Lmx1a,
which are able to directly convert mouse and human fi-
broblasts to functional dopaminergic neurons. They have
showed that the directly converted dopamine neurons
have electro-physiological activity similar to the dopa-
mine neurons [123]. Kim et al. reported that lentiviral
expression of eight different transcription factors of
Acsl1, Mytl1, Brn2, Lmx1a, Lmx1b, Nurr1, Pitx3 and
EN1 in mouse fibroblasts is sufficient to induce midbrain
dopaminergic neurons-like cells expressing dopamine
neuron marker of Pitx3. They found that two of the
eight transcription factors, Acsl1 and Pitx3 are necessary
for inducing fibroblast to dopamine neurons. Import-
antly these directly reprogrammed DA neurons function
in mouse model of PD [126]. Kim et al. combined the
transcription factors of which induced the fibroblasts to
the neural progenitor cells (NPCs) and the culture envir-
onment containing SHH and FGF8 to induce the dopa-
minergic neuronal progenitors which can produce the
dopamine neurons expressing TH and releasing dopa-
mine [125].
Since most direct reprogramming methods are using
lentiviral vectors to express the genes related to develop-
ment of DA neurons, these transgenes may integrate
into the genome of the iDA neurons and produce muta-
genesis in iDA neurons. In addition, the fibroblasts from
PD patients may also carry the genetic mutations of the
genes such as SNCA, Parkin, LRRK2, and GBA as we
discussed in iPSCs. These issues can cause safety con-
cerns for clinical use of the directly reprogrammed DA
neurons. However, the research advancement will even-
tually overcome these issues and bring these cells to
clinical trials for PD.
Future aspects and challenges for cell-based therapy of
PD
As we discussed above, the NSCs and DA neurons from
fetal brain and hESCs are not suitable for clinical use be-
cause of their immune-rejections and ethical issues. The
availability of iPSCs and iDA neurons paved the road for
autologous cell-based therapy of PD. A clinical trial to
use iPSCs for the treatment of eye disorders has been
initiated in Japan. However, several aspects of iPSCs
need to be resolved before they go to clinical use. These
include low yields of DA neurons, genetic and epigenetic
abnormalities, and the safety of iPSC-derived cells.
Low yield
Though low yields of fully reprogrammed cells are a re-
curring problem, this is by no means an inherent prop-
erty of iPSC generation, and there will continue to be
yield improvements in the future. The original yields of
0.05 % have been increased by various factors, such as
the addition of VPA and other chemicals in generating
iPSCs [127]. Yamanaka et al. proposes the stochastic
model, under which most or all differentiated cells have
the potential to become iPSCs. Indeed, though iPSCs are
typically generated from fibroblast cells, they have been
generated from a wide array of cells from all three cell lines
(mesodermal, endodermal, and ectodermal). Stadtfeld et al.
[101] used liver cells; Aoi et al. [128] used stomach and liver
cells; Aasen et al. [129] used human hair cells, indicating
that cells can theoretically be sourced from virtually any-
where on the adult human, with varying yields across ex-
periments. In fact, Aasen et al. found that keratinocyte-
derived iPSCs from adult human hairs were indistinguish-
able from ESCs and generated with a 100-fold increase in
efficiency compared to human fibroblast reprogramming
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[129]. In any case, future avenues must include compari-
sons between method efficiencies, with the goal of optimiz-
ing protocols for maximum cell yield of iPS cells.
Genetic and epigenetic abnormalities
There remain concerns regarding epigenetic memory in
iPSCs and iDA neurons towards a cell fate related to
their donor source and otherwise maintaining a repro-
gramming signature after differentiation [130, 131]. The
lentivirus or retrovirus-mediated reprogramming
methods should be replaced by non-integrating vectors
to express the reprogramming genes or combine with
small molecules for the generation of clinical applicable
iPS cells [132]. Some iPSCs from PD patients may also
contain gene mutations such as point mutations,
chromosomal structure variations, gene duplications,
and deletions in the genes of SNCA, Parkin, LRRK2,
GBA or others [103, 133–137]. The cells derived from
iPSCs with genetic mutations are not suitable for direct
transplantation as the functions of cells are affected by
the genetic mutations. Several protocols have been de-
veloped to correct the mutation in PD patient-derived
iPSCs. It was reported that the SNCA mutation (A53T)
in iPSCs could be repaired by a zinc-finger nuclease
(ZFN)-mediated nuclease approach and the ability to dif-
ferentiate into dopaminergic neurons was not affected
by genetic correction of the A53T mutation in the
patient-derived iPSCs. PCR genotyping and sequencing
analysis confirmed the correctly repaired patient-derived
iPSC lines [137]. A recent study showed that the LRRK2
G2019S mutation in iPSCs was corrected and the
LRRK2 mutation correction produced phenotype rescue
in differentiated neurons [103].
Safety and purity
To obtain iPSC-derived NSCs or DA neurons for the
treatment of PD, it is required that the residues of undif-
ferentiated iPSCs should be less than 1 % to avoid tera-
toma formation after transplantation. Approaches have
been developed to sort the iPSC-derived cells with FACS
or other non-invasive magnetic selection. In addition,
the cell culture should be carried in feeder-free condi-
tions to avoid the contamination of animal sources. Cur-
rently, murine-derived feeder cells are widely used to
maintain hESCs and hiPSCs. Also, culture medium con-
taining fetal bovine serum (FBS) is normally used for the
culture of these feeder cells. This will cause the allogenic
cell contamination of the iPSC-derived cells. A recent
study developed a feeder-free system to culture the
hESCs and iPSCs in the StemFit™ medium, taking a big
step toward making clinically-applicable GMP-standard
cells [138].
Onwards to the clinic: conclusion
Cell replacement therapy is a promising avenue for the
treatment of PD and other neurodegenerative disorders.
The use of all cell sources derived – fetal NSCs, ESCs ,
iPSCs and iDA neurons – is fraught with ethical, logis-
tical, and safety concerns. However, scientific research is
making great progress in the development and
characterization of iPSC derived cells for PD. iPSCs and
their derivatives injected into animal models have shown
promise in treatment of disorders such as PD; however,
iPSCs have not been used in clinical trials for PD. There
are some limitations/disadvantages associated with
iPSCs. A relevant therapeutic progenitor or mature cell
type may be identified and grafted in such treatments; in
the case of PD, the options are, of course, iPSC-derived
NSCs and iPSC-derived DA neurons. Theoretically, these
two should act just like their non-iPSC derived counter-
parts –in actuality, because of the concerns mentioned
above, the unique iPSC heritage of such cells sometimes
poses its own unique set of problems.
Pre-clinical studies on viability might also be necessary
to establish the scope of the treatment. iPSCs would not
be moved to clinical trials at least until iPSCs are better
understood and efficient and safe methods for repro-
gramming and gene correction are developed. The pace
of progress will no doubt continue to speed along in the
years to come, and it is therefore quite likely that within
our lifetime we will witness the jump from dish to clinic.
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